Skip to content
Back to meeting Original
Targeted Oncology· @TargetedOnc · X·· 1 day agoScore70

SAFFRON

Body

#ESMO26 | SAFFRON

After osimertinib progression, can targeting MET help?

Osimertinib + savolitinib improved PFS (7.6 vs 5.4 mo; HR 0.55) and OS (17.8 vs 12.9 mo; HR 0.68) vs chemotherapy in MET-driven EGFR-mutant NSCLC.

— @AmandaSunMD | #ESMO26 Takeover, Oct 25

52 views · 0 likes · 0 reposts · 0 replies

Source: Targeted Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.